The guidance cut is the most significant signal — the lost customer revenue is not being replaced quickly enough. Traders should watch the upcoming 10-Q filing for segment-level detail and any updates on new biopharma customer wins. Given the prolonged revenue decline, UTMD may need to pivot to cost-cutting or M&A to stabilize earnings. The stock's 23% YTD gain (to $68.98) may face headwinds if the market reprices for lower growth.
Price Chart
Executive Summary
UTMD reported Q2 2026 revenue of $8.5M, down 14.3% YoY, and EPS of $0.844, down 10.1% YoY, reflecting the continued loss of its two largest customers (PendoTECH and China distributor). Management lowered full-year 2026 revenue guidance to a 10-13% decline from prior expectations of flat sales, as new product sales to biopharma customers have been slower than anticipated. The balance sheet remains debt-free with $87.5M cash, but the top-line trajectory and guidance cut signal ongoing headwinds.
Key Financial Metrics
Key Facts
- Q2 2026 revenue fell 14.3% to $8.53M vs $9.95M in Q2 2025; EPS declined 10.1% to $0.844 from $0.939
- Full-year 2026 revenue guidance lowered to a 10-13% decline (from prior expectation of flat vs 2025) due to slower-than-expected new product sales
- Loss of two former largest customers (PendoTECH OEM and China distributor) accounted for 75% of the Q2 revenue decline
- Litigation expense guidance raised: 2026 now expected to be less than $1.6M (vs $1.355M in 2025), reversing prior expectation of a decline
- Balance sheet remains strong with $87.5M cash and no debt; share repurchases minimal at $0.2M in 1H 2026 vs $6.7M in 1H 2025
Financial Impact
Revenue decline of $1.42M in Q2 and $2.41M in 1H; EPS decline of 10.1% in Q2. Full-year guidance implies $3-4M revenue shortfall vs prior plan.
Risk Factors
- Continued revenue concentration risk — two former customers accounted for $2.9M in 2025 sales with no replacement yet
- Litigation expenses could exceed the revised $1.6M estimate if cases go to trial
- Operating leverage works in reverse — fixed manufacturing overhead and G&A (health plan, litigation) compress margins on lower sales
- New product sales to biopharma OEM customers are developing slower than expected, delaying the revenue recovery
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001096906-26-001112 |
| Document: utmd-20260723_8k.htm | 0001096906-26-001112 |
| Document: 0001096906-26-001112-index-headers.html | 0001096906-26-001112 |
| Document: 0001096906-26-001112-index.html | 0001096906-26-001112 |
| Document: 0001096906-26-001112.txt | 0001096906-26-001112 |
| 8-K Data (Synthetic) | 0001096906-26-001112 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $71.13 $74.95 | ▲ +5.37% | ▲ +5.56% | $74.31 (+4.47%) |
Jul 23, 2026 10w ago | 8-K | $64.18 $71.42 | ▼ −11.28% | ▼ −7.97% | $74.31 (−15.78%) |
Apr 23, 2026 23w ago | 8-K | $67.87 $64.17 | ▲ +5.45% | ▲ +10.09% | $74.31 (−9.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access